Renovo, plc.

Template:Infobox Company

Renovo, plc. (Template:Lse) is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research[1], and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"[2] in 2009.

The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes[3].

## Products[edit | edit source]

Currently the company doesn't have a marketed product, though its pipeline includes one drug that has recently initiated phase III clinical development, three drugs in phase II clinical development, and 13 other pre-clinical candidates.

Drug  | Phase  | Action

|
|

Juvista | Phase III Clinical trial | scar prevention, also for vascular restenosis
Juvidex | Phase II Clinical trial | scar reduction, also for abdominal adhesions and eye scars
Prevascar | Phase II Clinical trial | scar prevention, also for nerves and eyes
Zesteem | Phase II Clinical trial | acute skin healing

## References[edit | edit source]

1. ↑ http://www.regenmednetwork.com/archive/january_2007_meeting/january_2007_meeting.html
2. ↑ http://www.renovo.com
3. ↑ http://www.renovo.com/content.asp?c_id=15

## External links[edit | edit source]

* www.renovo.com

Template:Med-company-stub